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Abstract 
The Implantable Cardioverter Defibrillator (ICD) has become the standard of care in 
patients with ischemic and non-ischemic cardiomyopathy who are at high risk for 
arrhythmic events and sudden cardiac death. Recurrent ventricular arrhythmias are 
common after ICD implantation and the majority of ICD recipients receive one or more 
shocks within a year of implantation. Although ICDs save lives, the shocks from these 
devices are associated with profound physical, emotional and psychological trauma, 
increased morbidity, and poor quality of life. More than half of these patients receive 
adjuvant antiarrhythmic drug therapy to circumvent episodes of recurrent ventricular and 
supraventricular arrhythmia. Electrical storm is also common in this high risk population 
and requires prompt therapeutic intervention with antiarrhythmic drug therapy. Evidence 
suggests that antiarrhythmic drugs including β-blockers, sotalol, amiodarone and 
azimilide, are effective at reducing the shock burden in ICD patients. Although, some 
antiarrhythmic drugs can interfere with proper ICD function, cautious administration and 
subsequent monitoring with adjustment of device algorithms can help curtail this 
problem. Data supporting the need for and potential risk-benefits of adjuvant 
antiarrhythmic drug therapy in ICD patients are described in this paper.  
Synopsis 
The Implantable Cardioverter Defibrillator (ICD) has become standard of care in patients 
with ischemic and non-ischemic cardiomyopathy. Although ICD saves life, ICD shocks 
are emotionally and physically debilitating. Adjuvant antiarrhythmic drug therapy with β-
blockers, sotalol, amiodarone and azimilide is effective in preventing ICD shocks. The 
article examines benefits, pitfalls of adjuvant antiarrhythmic drug therapy in patients with 
an ICD.  
Introduction 
Use of Implantable Cardioverter Defibrillators (ICD) have revolutionized the care 
of patients with ischemic and non-ischemic cardiomyopathy.1,2 The primitive ICD 
introduced in  the 1980s by Mirowski and colleagues has become much more 
sophisticated with programming capabilities, atrial and left ventricular leads, anti-
tachycardia pacing (ATP) algorithms, bi-ventricular pacing and cardioverting and 
defibrillating shocks.1,3 Similarly, indications for ICD implantation are expanding as 
well.4 Assessment for eligibility of an ICD implantation is considered one of the integral 
parts of management of cardiomyopathy patients due to mortality benefits. 1,2 
Consequently, the number of ICD implantations has increased significantly in the last 
decade with a concurrent decrease in the use of stand-alone antiarrhythmic drugs for 
ventricular arrhythmia indications.5-7  
            The ICD prevents sudden cardiac death (SCD) by terminating the episodes of 
ventricular tachycardia (VT) or ventricular fibrillation (VF), delivering ATP therapy or 
ICD shock. Therefore, patients with ICD typically receive one or more ICD therapies for 
spontaneous arrhythmias following implantation.1,8 Despite the technological evolution 
of ICD systems, more than 20% of  shocks that are delivered are due to supraventricular 
arrhythmia and are categorized as “inappropriate”.9-11 ICD shocks are physically and 
emotionally painful and most patients dread future shocks. 12 Many patients experience 
symptoms such as dizziness, palpitations, nervousness, flushing or even syncope before 
receiving an ICD shock.13 A higher incidence of depression and poor quality of life has 
been reported in patients who have received one of more ICD shocks, and adverse 
psychological outcomes directly correlate to the number of ICD shocks. 14-16 
        Several anti-arrhythmic drugs have been shown to reduce ICD therapies including 
shocks. Upward of 70% patients end up receive adjuvant antiarrhythmic drug therapy for 
this indication. 17,18 This was best exemplified in the device arm of the Antiarrythmic 
versus Implantable Defibrillator (AVID) trial. 19 About 18% patients in the ICD arm of 
the AVID trial had to be started on adjuvant antiarrhythmic drug therapy (amiodarone 
42%, sotalol 21%, and mexiletine 20%) to reduce frequent ICD shocks and to prevent 
recurrent ventricular arrhythmia. 19 Adjuvant antiarrhythmic drug therapy in these 
crossover patients reduced the one year arrhythmia event rate from 90% to 64%. Potential 
benefits, pitfalls, need for caution and the clinical trials of adjuvant antiarrhythmic drugs 
in ICD implanted patients will be discussed in this review.  
Clinical trials supporting the efficacy of adjuvant antiarrhythmic drug therapy 
Major clinical trials establishing the role of adjuvant antiarrhythmic drugs and 
their principle outcomes are listed in table 1.  The majority of patients enrolled in these 
trials received an ICD for secondary prevention of SCD or a documented episode of 
VT/VF.  
Sotalol was one of the first antiarrhythmic drugs tested for such an indication by 
Pacifico et al.20 In this double-blind prospective multicenter trial, 302 patients with ICDs 
were randomized to receive either 160-320 mg of d,l-sotalol (n=151)  or matching 
placebo (n=151) and were followed for 12 months. In this study, compared to placebo, 
treatment with sotalol led to a 48% risk reduction of all-cause mortality and delivery of 
first shock for any reason (Figure 1). When ICD shock was categorized as appropriate vs. 
inappropriate, there was a 64% risk reduction for all-cause death or first inappropriate 
shock and a 44% risk reduction for all-cause death or first appropriate shock.  The results 
remained unchanged when stratified by left ventricular ejection fraction or concomitant 
use of β-blockers.  The mean frequency of all-cause shock was 1.43 ± 3.53 in the sotalol 
group compared to 3.89 ± 10.65 in control group. Rate of discontinuation of the drug was 
about 33% at one year in the sotalol and placebo groups. Patients receiving sotalol were 
more likely to have bradycardia and QT prolongation, but only one episode of torsades de 
pointes (TdP) was reported. Similar efficacy of sotalol was reported in another small 
scale study of 46 patients.21 Similar to sotalol, dofetilide, a pure class IKr blocker, was 
shown to be effective in increasing the median time to first all-cause ICD shocks in a 
study by O’Toole et al.27 However, dofetilide administration was associated with a high 
incidence of TdP in this study.   
 Although most of the patients with ICDs receive β-blockers as part of a 
comprehensive medical regimen, it is worth underscoring the importance of β-adrenergic 
blockade in prevention of ICD shocks. Simple β-blockers have been shown to be at least 
equally or more effective than sotalol in the prevention of ICD shocks. In a small 
prospective trial of 100 patients with an existing ICD, Kettering et al showed that 
metoprolol was as effective as sotalol in preventing VT/VF and resultant ICD 
interventions. 23 Similarly, in a post hoc analysis of 691 patients with ischemic 
cardiomyopathy in the Multicenter Automatic Defibrillator Implantation Trial II  
(MADIT-II), patients receiving higher doses of metoprolol, atenolol and carvedilol had a 
52% relative risk reduction for recurrent VT/VF requiring ICD therapy as compared to 
patients not on β-blockers. Superior efficacy of metoprolol to sotalol was demonstrated in 
a small prospective study of 70 patients with an ICD.22 The probability of reaching a 
combined end point of symptomatic recurrence of fast VT or VF, or death was 
significantly lower at 1 and 2 years in the metoprolol group (83% and 74% respectively) 
as compared to the sotalol group (47% and 38% respectively, p = 0.004). ICD 
interventions in the form of ATP and shocks were significantly lower in the metoprolol 
compared to the sotalol arm.  
 Azimilide is a novel class III drug that blocks both the rapid and slow component 
of the delayed rectifier cardiac potassium current, and is effective in a variety of 
supraventricular arrhythmias.28 Recent clinical trials have demonstrated its role in the 
prevention of ICD shocks. In a dose-range, pilot study of 172 ICD patients, Singer at el 
demonstrated that  azimilide reduced the relative risk of appropriate ICD therapy (Shocks 
and ATP) by 69% at all administered doses (35 mg, 75 mg or 125 mg) as compared to 
placebo at one year follow-up. Azimilide did not have adverse effects on left ventricular 
function, resting heart rate, defibrillation or pacing thresholds. 24   
The efficacy of azimilide was further investigated by Dorian et al in the large 
prospective double-blind trial, SHock Inhibition Evaluation with azimiLiDe25 (SHIELD) 
in 633 ICD recipients. The 2 primary end points of this trial were (1) all-cause shocks 
plus symptomatic tachyarrhythmias terminated by ATP and (2) all-cause shocks. A single 
secondary end point was all appropriate ICD therapies. Azimilide was tested in 75 mg 
and 125 mg doses.  At a median follow-up of 1 year, azimilide significantly reduced the 
first primary end point of all-cause shocks plus symptomatic arrhythmia terminated by 
ATP in both doses as compared to placebo (HR: 0.43 for 75 mg dose and HR: 0.53 for 
125 mg dose) (Figure 2). There was no statistically significant difference in efficacy 
between the two doses, and there was a trend toward a reduction in the primary end point 
of all-cause shock alone with both doses of azimilide.  
The secondary end point of all appropriate ICD therapies (shocks or ATPs) was 
reduced by both 75 and 125 mg/day azimilide (HR = 0.52 and 0.38 with p = 0.017 and 
0.0004 respectively, Figure 2) with a trend toward a more significant effect at the 125 mg 
dose. Additional analysis revealed that treatment with azimilide led to significant 
decrease in the incidence of all ICD interventions and all-cause shocks with an increased 
inter-event interval suggesting a possible benefit in the treatment of electrical storm. This 
was confirmed by subsequent analysis of SHEILD data by Hohnloser et al who showed 
that treatment with 75 mg and 125 mg/day azimilide reduced the risk of electrical storm 
by 37% and 55% respectively as compared to placebo. These beneficial effects of 
azimilide translated into reduced emergency department visits and hospitalizations.29 
Azimilide was well tolerated as an addition to conventional therapy. About 86% 
patient were on concomitant β-blocker therapy suggesting that benefits of azimilide were 
over and above traditional therapy. The overall incidence of adverse events and rates of 
early discontinuation (35-36%) were similar to placebo.24-26 Azimilide therapy led to a 
dose dependent prolongation of the QT interval, however, TdP was reported in 5 patients 
without any consequences 25 One patient had severe but reversible neutropenia with 75 
mg of azimilide.25 In the context of the above data, azimilide is the first drug submitted to 
the Food and Drug Administration for use with an ICD and is currently under review to 
be used for this indication.  
 Amiodarone remains one of the most commonly used antiarrhythmic drugs, 
especially in patients with advanced cardiomyopathy due to its established efficacy and 
cardiac safety profile compared to other antiarrhythmic drugs. The OPTIC (Optimal 
Pharmacologic Therapy in Cardioverter Defibrillator Patients) study investigated the 
efficacy of β-blocker, sotalol and β-blocker plus amiodarone in the prevention of ICD 
shocks.26 The OPTIC investigators randomized 412 patients with an ICD to receive β-
blocker alone, sotalol alone, and amiodarone in addition to β-blocker and followed them 
for one year. The results showed that the patients treated with sotalol or amiodarone had 
reduced risk of shock of 56% compared to β-blocker alone. In addition, amiodarone plus 
β-blocker was more effective than β-blocker alone (HR = 0.27, p < 0.001) or sotalol (HR: 
0.43, p = 0.02) in preventing both appropriate and inappropriate ICD shocks (Figure 3). 
Mortality was not significantly different among the three groups and no cases of TdP 
were reported. Rates of study drug discontinuation at 1 year were 18.2% for amiodarone, 
23.5% for sotalol and 5.3% for β-blocker alone group.  Adverse pulmonary, thyroid, and 
bradycardic events were more common with amiodarone treatment.   
Similar to its congener amiodarone, dronedarone was effective in reducing the 
rate of appropriate ICD intervention during a 30 day follow-up in a small study.30 
Benefits of Adjuvant antiarrhythmic drug therapy 
 Clearly, antiarrhythmic drugs reduce the incidence of both appropriate as well as 
inappropriate ICD therapies (both ATP and Shock) by more than half. 20,25,26 Such a 
reduction in ICD shocks would be expected to decrease emergency department visits as 
well as the rate of hospitalization.25,29 A decrease in the number of ICD discharges also 
prolongs the battery life of the device.31 As such, antiarrhythmic drug therapy result in 
overall improvement in quality of life of ICD implanted patients. Additionally, most 
antiarrhythmic drugs tend to prolong the tachycardia cycle length and may render the 
tachycardia more hemodynamically stable and thus amenable to termination with ATP.32 
Some antiarrhythmic drugs may reduce the defibrillation threshold (DFT) and facilitate 
defibrillation of VT/VF as discussed below. 
About 10 to 30% patients with ICD develop electrical storm, defined as three or 
more episodes of hemodynamically destabilizing VT/VF occurring in a 24-hour period. 
Development of electrical storm is associated with increased morbidity, and a 40% 3-
month mortality.33-35 Although, recent clinical trials have suggested role of catheter 
ablation techniques as a first line treatment for electrical storm, antiarrhythmic drugs still 
remain the cornerstone for the therapy for electrical storm. Reversal of precipitating 
factors, optimization of β-blocker therapy and addition of intravenous amiodarone 
followed by oral maintenance dosing is required in most cases to abort and prevent 
recurrent ventricular arrhythmia.33,36 As outlined above, the investigational agent 
azimilide has been shown to reduce risk of electrical storm by 37-55%.37 The principle 
advantages of adjuvant antiarrhythmic drug therapy can be summarized as in Table 1.  
Drug-device Interaction  
A great deal of caution needs to be exercised when a new antiarrhythmic drug is 
started in a patient with an implanted device. Potential adverse drug-device interactions 
are listed in Table 2.  
One of the most important drug-device interactions is a drug-induced increase in 
defibrillation and pacing thresholds leading to failure of treatment of life threatening 
arrhythmia. Although most antiarrhythmic drugs increase the defibrillation threshold 
(DFT), some may lower it. In a sub-study of 94 patients from OPTIC, amiodarone plus β-
blocker therapy led to a small but statistically significant increase (1.29 J) in DFT after 8-
13 weeks of therapy.38 In contrast, treatment with sotalol and β-blocker was associated 
with decrease in DFT by 0.89 J and 1.67 J respectively. Careful testing of DFTs should 
be performed in all the patients, with special attention to those who have monophasic 
waveform ICDs, those with an epicardial lead system39, patients with a high DFT at 
baseline, and patients treated with high dose,40 chronic amiodarone. 41-44 
Azimilide has been shown to have minimal effects on the DFT or pacing 
thresholds in ICD patients.24,45 Similarly, dronedarone has been shown to have no effect 
on defibrillation safety margin or pacing thresholds at its therapeutic dose or higher.30,46 
Antiarrhythmic drugs are usually increase the cycle length of VT, which improve 
hemodynamic tolerability and effectiveness of ATP in most situations. The downside is 
that the drugs like amiodarone and sotalol may slow the tachycardia rate to such a degree 
that it becomes lower that the programmed tachycardia detection rate of the ICD leading 
to failure to sense VT.47 Appropriate adjustments in the detection algorithm are necessary 
when adjuvant antiarrhythmic drugs are instituted. Antiarrhythmic drugs, especially Class 
IC agents, may also affect the morphology of the QRS complex and thus impact 
morphology sensing and rhythm stability criterion leading to incorrect rhythm 
interpretation by the ICD and resultant inappropriate treatment.48  
Drug induced proarrhythmia, especially TdP, is rare but serious problem when 
drugs with Class III effects like azimilide, sotalol, dofetilide and amiodarone are used, 
especially in patients with compromised repolarization reserve.49 Extra-cardiac side 
effects of antiarrhythmic drugs like amiodarone are a limitation to its long term use. This 
may be less of an issue with new drugs like dronedarone or azimilide.46 
Expert Opinion 
 In conclusion, adjuvant antiarrhythmic drug therapy should be considered an 
integral part of the management of patients with an ICD. Unanswered questions are: 1) 
Which patients should receive adjuvant antiarrhytmic drug therapy?  2) When to start the 
therapy? 3) What drugs to start? 4) When to consider catheter based ablation techniques?  
The majority of clinical trials outlined above enrolled patients for whom the ICD 
was implanted for secondary prevention of SCD. Similar evidence in patients who have 
received the ICD for primary prevention is lacking. Such patients appear to have fewer 
device activations.50,51 In the context of a lower risk population, adjuvant antiarrhythmic 
drug therapy should be started only if one or more ICD shocks have been delivered, with 
the expectation that well designed therapy can reduce ICD shocks and improve quality of 
life. The timing of antiarrhythmic drug therapy in patients should always be based on best 
physician judgment and patient preference.  
It should be emphasized here that no drug has achieved approval for the 
prevention of ICD shocks, and we have no data to support early, prophylactic use. 
Although starting antiarrhythmic drug therapy before an ICD shock is delivered might be 
valuable, it should be kept in mind that antiarrhythmic drug therapy itself carries 
substantial risk.  
When patients need drugs because of frequent shocks, the weight of evidence 
supports optimizing β-blocker therapy. If they are ineffective or poorly tolerated, 
amiodarone, azimilide, or sotalol may provide benefit. Any antiarrhythmic drug 
prescribed to treat serious ventricular arrhythmias, including those that have triggered an 
ICD shock, should be started under observation not only to observe for toxicity, but also 
to gauge efficacy. If proarrhythmia occurs, it tends to become manifest during the early 
stages of therapy, as drug concentrations approach steady state. 
Catheter based mapping and ablation techniques have been considered a last 
resort treatment for patients with recurrent VT refractory to adjuvant drug therapy.52 
Although recent clinical trials support the role of catheter ablation techniques as a prime 
line treatment for prevention of recurrent ICD therapies including electrical storm, these 
techniques are invasive and results are operator dependent.53-55 Data supporting the use of 
catheter ablation therapy are limited and do not address issues such as quality of life and 
cost. We believe that antiarrhythmic drugs remain first line therapy for prevention of ICD 
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Table 1: Clinical trials summarizing benefits of adjuvant antiarrhythmic drug therapy. 











151  12 
months 
All-cause death or all-




Mean frequency of 
shocks due to any 
cause: 
Sotalol: 1.43 ± 
3.53* 





(80 to 400 
mg) 
Vs. placebo 
≈ 46  12 
months 






















VT treated by ATPs: 
Metoprolol: 20%* 
Sotalol: 49% 
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shocks and ATPs:  
Placebo: 36  
35 mg AZ: 10* 
75 mg AZ: 12* 












1 year All-cause shock and 
ATP: 
75 mg AZ: HR=0.43* 
125 mg AZ: HR=0.53* 
as compared to placebo 
All-cause shock: 
Tread towards 
























blocker: 10.3%* (HR: 
0.27 Vs. β-blocker, 
HR: 0.43 Vs. sotalol) 
 
 
            *, significant p value; AZ, azimilide; ATPs, antitachycardia pacing; HR, hazard 
ratio; ICD, implantable cardioverter defibrillator; VT, ventricular tachycardia; 
VF, ventricular fibrillation; SHIELD,  Shock Inhibition Evaluation with 
azimiLiDe; OPTIC, Optimal Pharmacologic Therapy in Cardioverter Defibrillator 

















Table 2: Benefits and Pitfalls of adjuvant antiarrhythmic drug therapy in ICD 
patients. 
Advantages and pitfalls of adjuvant antiarrhythmic drug therapy in patients with 
ICD 
Pros: 
- Decrease in appropriate ICD shocks due to suppression of recurrent VT/VF 
-Decrease in inappropriate ICD shocks due to reduced frequency and better rate control 
of supraventricular rhythm 
-Slowing of tachycardia leading to improved hemodynamic tolerance 
-Slowing of rate of tachycardia facilitating successful termination by ATP 
-Prolongation of ICD battery life  
-Decrease in frequency of symptomatic non-sustained ventricular arrhythmias 
-Prevention and better treatment of electrical storm 
-Improved quality of life and sense of well-being 
-Reduced defibrillation threshold facilitating easier defibrillation 
-Improved control of maximal sinus rate 
-Reduced rate of recurrent ICD related hospitalizations 
Cons: 
-Interference in ICD function due to 
-Increase in defibrillation threshold 
-Increase in pacing threshold 
-Interference in accurate arrhythmia detection due to 
-Slowing of rate of Ventricular tachycardia  
-Decrease in amplitude of electrocardiogram interfering with sensing 




-Torsades de pointes 
-Impairment of myocardial function 
-Extra-cardiac toxicity 
Reproduced with permission from reference 8. 
Figure Legends: 
Figure 1: The Kaplan-Meier time-to-event curves for combined end point of all-cause 
death or all-cause shock in control and sotalol group. Treatment with sotalol 
reduced the relative risk of combined end point by 48%. Reproduced with 
permission from reference 20. 
Figure 2: A: Effect of azimilide (AZ) on all-cause shocks plus symptomatic 
tachyarrhythmias terminated by antitachycardia pacing. Treatment with 75 
mg/day and 125 mg/day azimilide significantly reduced risk of all-cause shocks 
and symptomatic tachyarrhythmia by 57% and 47% respectively. B: Effect of 
azimilide on all appropriate ICD therapies. Treatment with 75mg/day and 125 
mg/day of azimilide significantly reduced the risk of all appropriate ICD therapies 
by 48% and 62% respectively. Reproduced with permission from reference 25. 
Figure 3: Cumulative risk of shock in all three treatment groups. Amiodarone plus β-
blocker significantly reduced the risk of shock compared with β-blocker alone 
(HR: 0.27, p < 0.001) and sotalol (HR: 0.43, p = 0.02). Reproduced with 
permission from reference 26.  
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